Family offices bet on women's health and care as a structural investment thesis
October marked a turning point in the investment behaviour of global family offices. After a slow September, the investment firms of ultra-wealthy families closed 56 direct investments in startups, an increase of roughly 30% compared to the previous month, according to data from Fintrx, a private wealth intelligence platform. The numerical uptick matters, but what matters more is where the money went: women's health, clinical data infrastructure and paid family caregivers under public programmes. That is no coincidence. It is a logic that has been building for years.
The thematic concentration of October reveals something that capital-flow data tends to obscure: when family offices act with conviction, they do not diversify by sector but by hypothesis. And the hypothesis they are executing with the greatest consistency is that the healthcare system has gaps in data, coverage and labour that conventional institutional capital has ignored for decades. Those gaps are becoming markets.
The Emerson Collective's move and what it reveals about long-term capital
The Emerson Collective, the investment and philanthropic vehicle of Laurene Powell Jobs, was the most active investor of the month with three bets on health startups. The three cover distinct parts of the system: a Medicare Advantage plan operator, a clinical data platform for artificial intelligence models, and a company focused specifically on women's research data.
The Emerson Collective's participation in Devoted Health's $555 million Series G round — part of a total $1.18 billion transaction that includes a secondary offering to existing shareholders — places this family office within a consortium that includes Advent, Temasek, GIC, Franklin Templeton and Andreessen Horowitz. That composition is not trivial: it means that capital from ultra-wealthy families is not arriving as a substitute for institutional capital, but as a legitimate participant in scale rounds. Devoted Health will use the funds to expand into five additional states, reaching a presence in 34, with a model that combines the functions of medical provider and insurer within Medicare Advantage.
Emerson Collective's other two investments are structurally distinct but conceptually coherent. BioStack, which closed a $9.5 million seed round, aggregates clinical records from different institutions to build training datasets for artificial intelligence models in healthcare. Collective X Health, which raised $3.2 million in a pre-seed round, compiles and licenses peer-reviewed research with a focus specifically on women's data. Both operate on the same terrain: the scarcity of structured, representative clinical data as a bottleneck for the sector.
What connects the three investments is not the size of the rounds but the coherence of the thesis: the North American healthcare system has a severe problem of incomplete information, and that problem is not a technical failure — it is a historical consequence of which populations and which questions were considered priorities when the existing data structures were built. Family offices are betting that correcting that distortion generates commercial value, not merely social impact.
The structural logic behind the shift toward health and care
Family offices' positioning in health did not begin in October. A Citi Wealth survey published in September already showed that the sector was the second priority in direct investment for these firms, with 32% of respondents citing it, behind only artificial intelligence at 51%. The fact that health and data technology converge in the same operations — as in BioStack or in the thesis underpinning Devoted Health — suggests that the separation between those two categories is more editorial than substantive.
The investment by Pivotal Ventures, the family office linked to Melinda French Gates, in Abby Care's $82 million Series C adds another dimension to the pattern. Abby Care trains and certifies family members as paid caregivers under Medicaid and Medicare programmes. It is a model that transforms informal, unpaid labour into formal, paid work within the public health system. Abby Care's CEO and founder, Havi Nguyen, began navigating the Medicaid system at the age of 9 as a caregiver for her sisters and, later, for her grandparents. Erin Harkless Moore, who manages Pivotal Ventures' investments, stated publicly that they look for teams that understand the problem deeply and have built models adjusted to the realities of the healthcare system as it exists today, not as it should exist in an ideal scenario.
That statement is more substantial than it might appear. It reflects an investment criterion that prioritises regulatory and operational understanding over the originality of an idea. In a sector where the distance between a model on paper and adoption by public payers can take years, the founder's institutional knowledge functions as a more durable barrier to entry than the technology itself.
The structural logic underlying these investments has three layers. The first is demographic: the ageing of the North American population increases pressure on Medicare Advantage and long-term care services. The second is about the labour market: there is a severe shortage of certified caregivers, and models like Abby Care's attack that problem from the supply side, not the demand side. The third is informational: artificial intelligence models in healthcare are only as good as the data on which they are trained, and if that data systematically excludes women or is fragmented across institutions with no interoperability, the resulting models inherit those limitations.
Patient capital as a competitive advantage in the face of slow adoption structures
There is a reason family offices hold a favourable position in health that conventional venture capital funds do not easily replicate: the time horizon. Venture capital funds operate under defined life cycles, generally between ten and twelve years, with return pressure that pushes toward early exits or rapid-growth models. Family investment firms do not have that constraint by nature. They can sustain positions through regulatory approval cycles, public payer contracts, gradual geographic expansions and the construction of clinical datasets that take years to become commercially valuable.
That margin of time is not only financial. It is operational. Devoted Health has had Emerson Collective as an investor for years — the firm also participated in earlier rounds from 2021 onwards — and that continuity produces a different kind of relationship between investor and company: less exit pressure, more accumulated knowledge about the dynamics of the sector. There is no guarantee that this translates into better returns, but it does produce different conditions for execution.
The risks in models like Devoted Health's are well known and not trivial: scaling a Medicare Advantage operator means building provider networks in each new state, managing medical costs that can deviate from actuarial projections, maintaining regulatory compliance under federal programmes and competing against established insurers with decades of infrastructure. The expansion into five new states is a genuine growth step, but it is also an exercise in multiplying operational variables that the $555 million round does not resolve on its own.
For BioStack and Collective X Health, the challenges are different. Both operate at a stage where the business model is still being validated. BioStack needs to demonstrate that its training datasets produce clinical models that are superior to those built with alternative sources. Collective X Health needs to convince pharmaceutical companies, health systems or academic researchers that the specifically female data it licenses justifies the cost and quality standards. The rounds of $9.5 million and $3.2 million respectively buy time, not certainty.
What October signals about the next investment cycle in health
The October pattern is not simply a monthly uptick. It is the observable manifestation of a reorientation that has been taking shape for years in the way highly concentrated private capital conceives of healthcare: not as a regulated and difficult sector, but as a system with specific structural failures that generate value-capture opportunities proportional to the magnitude of the problem.
The data gap in women's health, the shortage of caregivers within public systems, the fragmentation of clinical records that limits the development of artificial intelligence models, and the complexity of navigating Medicare and Medicaid as a private operator are four distinct problems with one characteristic in common: they were ignored for decades not because they were technically unsolvable, but because the existing incentive structures did not point toward them. Family offices are arriving in those spaces with capital that does not need an exit in 36 months, and that changes the type of company that can be built.
The real risk of this optimistic reading is opacity: the 30% increase in deal flow does not reveal the past returns of these same firms in healthcare, nor does it confirm that the thematic hypothesis is correct. The North American healthcare market has generated enough failures of well-intentioned capital for monthly activity signals to be taken with the necessary distance. What can be stated with greater grounding is that the structural conditions that make these markets attractive — demographics, the shortage of specialised labour, the limitations of existing clinical data — are not resolved in the short term. That does not guarantee returns, but it does sustain the argument that the direction of capital flow is not arbitrary.
October's concentration in women's health, care and clinical data signals something more specific than a booming sector: it signals that there is capital with sufficient patience and thematic conviction to bet that the system's oldest distortions are also the most profitable to correct.
